RxDoctor Payments DataLook up a doctor →

Shawn Dhillon, MD

Internal Medicine · Baltimore, MDNPI 1215914437

Payments from drug & device makers

$226,833in general payments, 2019–2025

Across 1,570 payments — averaging $144.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$66K
  • Bayer$58K
  • AstraZeneca$50K
  • AbbVie$12K
  • Kowa Pharmaceuticals America, Inc.$9K
  • Amgen$7K
  • plus $24K from 54 others

What the payments were for

  • Consulting fees$21,56010%
  • Speaking & faculty fees$120,98753%
  • Travel & lodging$41,26618%
  • Food & beverage$42,50919%
  • Education$5110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amarin Pharma, Inc.154$65,831
Bayer137$58,256
AstraZeneca(2 entities)174$49,571
AbbVie(2 entities)132$12,162
Kowa Pharmaceuticals America, Inc.73$9,366
Amgen(2 entities)189$7,162
Pfizer52$6,588
Viiv Healthcare Company111$2,536
Novo Nordisk81$2,058
Mallinckrodt Hospital Products Inc.44$1,283
Dexcom, Inc.12$975
Akebia Therapeutics Inc48$970
Novartis22$957
Astellas Pharma US Inc33$751
Johnson & Johnson19$648
Gilead15$587
ANI Pharmaceuticals, Inc.14$485
Sanofi-aventis U.S. LLC8$445
Esperion Therapeutics, Inc.16$364
Travere Therapeutics, Inc.19$356
Otsuka America Pharmaceutical, Inc.15$351
Boehringer Ingelheim9$330
E.r. Squibb & Sons, L.L.C.7$321
GSK11$317
Sumitomo Pharma America, Inc.14$288
Vifor Pharma, Inc.15$255
Cequr Corporation2$245
Protega Pharmaceutials Inc5$235
Merck16$231
Fresenius USA Marketing, Inc.12$225
Lilly USA, LLC13$223
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)12$221
Calliditas Therapeutics US Inc.9$173
Idorsia Pharmaceuticals US Inc3$164
Exact Sciences4$155
Globus Medical1$124
BETA Bionics, Inc.1$114
Urovant Sciences Inc1$114
Phadia US Inc.2$107
Sunovion Pharmaceuticals Inc.5$103
Corcept Therapeutics5$100
Ironwood Pharmaceuticals, Inc5$74
Mylan Specialty L.p.1$74
Lexicon Pharmaceuticals, Inc.4$71
Tactile Systems Technology Inc1$70
Cashflow Solutions, LLC4$68
Eisai Inc.3$68
Abbott3$62
Biohaven Pharmaceutical Holding Company Ltd.3$62
Verona Pharma, Inc.4$61
Ultragenyx Pharmaceutical Inc.3$56
Hikma Pharmaceuticals USA3$56
Daiichi Sankyo Inc.3$54
Paratek Pharmaceuticals, Inc.2$46
Sanofi Pasteur Inc.3$43
Collegium Pharmaceutical, Inc.2$40
Alk-abello, Inc2$30
Valeritas, Inc.1$22
Scpharmaceuticals Inc.1$21
Impel Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,833 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$4,537,270
Medicare patients
269
Services billed
13,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol210$210,785
OzempicSemaglutide136$155,942
KerendiaFinerenone99$131,452
DovatoDolutegravir Sodium/Lamivudine20$59,579
RybelsusSemaglutide26$48,664
MounjaroTirzepatide35$46,812
EliquisApixaban45$41,801
LinzessLinaclotide47$40,428
GemtesaVibegron52$28,198
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$20,859
JardianceEmpagliflozin16$19,808
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,833
Breo ElliptaFluticasone/Vilanterol23$9,664
DapagliflozinDapagliflozin Propanediol16$8,606
Naloxone Hcl76$6,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$49,571$235,567258 claims
Novo NordiskOzempic, Rybelsus$2,058$204,606162 claims
BayerKerendia$58,256$131,45299 claims
Viiv Healthcare CompanyDovato$2,536$59,57920 claims
Lilly USA, LLCMounjaro$223$46,81235 claims
PfizerEliquis$6,588$41,80145 claims
AbbVieLinzess$12,162$40,42847 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$317$32,64562 claims
Sumitomo Pharma America, Inc.Gemtesa$288$28,19852 claims
Boehringer IngelheimJardiance$330$19,80816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →